IMPDH inhibitors could treat ALL

Print Friendly, PDF & Email


Micrograph showing ALL
A mutation that leads to relapse in patients with acute lymphoblastic leukemia (ALL) also causes a weakness that could be exploited to kill leukemia cells, according to research published in Nature. Investigators found evidence to suggest that mutations in the NT5C2 gene make leukemic cells resistant to a common chemotherapy... [Read Article]
Print Friendly, PDF & Email

CAR T-cell therapy on fast track in US, EU

Print Friendly, PDF & Email


Tisagenlecleucel (Kymriah)
Photo from Novartis
The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah, formerly CTL019) is getting fast-tracked in the United States (US) and European Union (EU). The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for tisagenlecleucel for the treatment of adults... [Read Article]
Print Friendly, PDF & Email

Gene variants associated with high-risk pediatric ALL

Print Friendly, PDF & Email


Jun J. Yang, PhD
Photo from Seth Dixon,
St. Jude Children’s
Research Hospital
New research has revealed germline variations associated with high-risk acute lymphoblastic leukemia (ALL) in children. Researchers sequenced the TP53 tumor suppressor gene in nearly 4000 children with ALL and identified 22 pathogenic germline variants. These variants were associated with inferior survival... [Read Article]
Print Friendly, PDF & Email

EC approves new formulation of pegaspargase

Print Friendly, PDF & Email


Micrograph showing
acute lymphoblastic leukemia
The European Commission (EC) has granted marketing authorization for a lyophilized formulation of pegaspargase (ONCASPAR). The product is intended for use as a component of antineoplastic combination therapy in acute lymphoblastic leukemia patients of all ages. The EC’s approval authorizes Shire to market lyophilized pegaspargase in the... [Read Article]
Print Friendly, PDF & Email